Plus Therapeutics downgraded to Hold from Buy at D. Boral Capital

D. Boral Capital downgraded Plus Therapeutics (PSTV) to Hold from Buy without a price target after the company announced a reverse stock split as part of a process to improve its capital structure. The firm intends to revisit its outlook once the reverse split is determined and effective, and the stock “has had time to stabilize post-split.” The split should position Plus Therapeutics to better address its capital needs, meet Nasdaq listing requirements, all with an improved capital structure, the analyst tells investors in a research note.